drugset / Trial / NCT05924997
Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-arm, phase Ib/II trial . The objective of this study is to evaluate the efficacy and safety of adebrelimab, camrelizumab plus apatinib as first-line therapy in patients with advanced hepatocellular carcinoma
Timeline
- Start
- 2023-07-01
- Primary completion
- 2025-06-01
- Completion
- 2026-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | 10 mg/kg | — |
| Subject | Adebrelimab | Monoclonal antibody | 20 mg/kg | — |
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | — |
| Subject | Rivoceranib | Small molecule | 250 mg | — |